Synergistic effect of glutathione and IgG4 in immune evasion and the implication for cancer immunotherapy*

被引:12
作者
Zhang, Weifeng [1 ]
Quan, Yan [2 ]
Ma, Xiaonan [1 ]
Zeng, Liting [1 ]
Li, Jirui [1 ]
Chen, Shuqi [1 ]
Su, Meng [1 ]
Hong, Liangli [1 ,2 ]
Li, Penghao [1 ,3 ]
Wang, Hui [1 ]
Xu, Qian [1 ]
Zhao, Chanyuan [1 ]
Zhu, Xiaoqing [1 ]
Geng, Yiqun [1 ]
Yan, Xiaomiao [3 ]
Fang, Zheng [4 ]
Chen, Muwang [4 ]
Tian, Dongping [1 ]
Su, Min [1 ]
Chen, Xueling [1 ]
Gu, Jiang [1 ,3 ,5 ]
机构
[1] Shantou Univ Med Coll, Prov Key Lab Mol Pathol & Personalized Med, Ctr Collaborat & Creat Ctr, Dept Pathol & Pathophysiol, Shantou, Guangdong, Peoples R China
[2] Shantou Univ Med Coll, Affiliated Hosp 1, Shantou, Peoples R China
[3] Jinjiang Hosp Maternal & Child Hlth Care, Jinxin Res Inst Reprod Med & Genet, 66 Jingxiu Rd, Chengdu, Peoples R China
[4] Mot China Grp Co Ltd, Xiamen, Peoples R China
[5] Shantou Univ Med Coll, Dept Pathol, 22 Xinling Rd, Shantou 515031, Peoples R China
来源
REDOX BIOLOGY | 2023年 / 60卷
基金
中国国家自然科学基金;
关键词
Immunoglobulin G4; Glutathione; Immunosuppression; Immune evasion; Hyperprogressive disease; Immunotherapy; GENOMIC ALTERATIONS; IMMUNOGLOBULIN G4; LUNG-CANCER; ANTIBODY; KRAS; COMPLEMENT; ARM; INHIBITION; METABOLISM; MECHANISMS;
D O I
10.1016/j.redox.2023.102608
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: We recently reported a novel IgG4-centered immune evasion mechanism in cancer, and this was achieved mostly through the Fc-Fc reaction of increased IgG4 to cancer-bound IgG in cancer microenvironment. The mechanism was suggested to be related to cancer hyperprogressive disease (HPD) which is a side-effect often associated to IgG4 subtype PD-1 antibody immunotherapy. HPD was reported to occur in cancers with certain mutated genes including KRAS and such mutations are often associated to glutathione (GSH) synthesis. There-fore, we hypothesize that IgG4 and GSH may play a synergistic role in local immunosuppression of cancer.Methods: Quantitatively analyzed the distribution and abundance of GSH and IgG4 in human cancer samples with ELISA and immunohistochemistry. The interactions between GSH and IgG4 were examined with Electrophoresis and Western Blot. The synergistic effects of the two on classic immune responses were investigated in vitro. The combined effects were also tested in a lung cancer model and a skin graft model in mice.Results: We detected significant increases of both GSH and IgG4 in the microenvironment of lung cancer, esophageal cancer, and colon cancer tissues. GSH disrupted the disulfide bond of IgG4 heavy chain and enhanced IgG4's ability of Fc-Fc reaction to immobilized IgG subtypes. Combined administration of IgG4 and GSH augmented the inhibitory effect of IgG4 on the classic ADCC, ADCP, and CDC reactions. Local administration of IgG4/GSH achieved the most obvious effect of accelerating cancer growth in the mouse lung cancer model. The same combination prolonged the survival of skin grafts between two different strains of mouse. In both models, immune cells and several cytokines were found to shift to the state of immune tolerance.Conclusion: Combined application of GSH and IgG4 can promote tumor growth and protect skin graft. The mechanism may be achieved through the effect of the Fc-Fc reaction between IgG4 and other tissue-bound IgG subtypes resulting in local immunosuppression. This reaction was facilitated by increased GSH to dissociate the two heavy chains of IgG4 Fc fragment at its disulfide bonds. Our findings unveiled the interaction between the redox system and the immune systems in cancer microenvironment. It offers a sensible explanation for HPD and provides new possibilities for manipulating this mechanism for cancer immunotherapy.
引用
收藏
页数:12
相关论文
共 59 条
[1]   Immunoglobulin G4: an odd antibody [J].
Aalberse, R. C. ;
Stapel, S. O. ;
Schuurman, J. ;
Rispens, T. .
CLINICAL AND EXPERIMENTAL ALLERGY, 2009, 39 (04) :469-477
[2]   Concurrent Mutations in STK11 and KEAP1 is Associated with Resistance to PD-(L) 1 Blockade in Patients with NSCLC Despite High TMB [J].
Arbour, K. ;
Shen, R. ;
Plodkowski, A. ;
Rizvi, H. ;
Ni, A. ;
Long, N. ;
Halpenny, D. ;
Sanchez-Vega, F. ;
Rudin, C. ;
Riely, G. ;
Hellmann, M. .
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) :S424-S424
[3]   Association Between Immunoglobulin G4-related Disease and Malignancy within 12 Years after Diagnosis: An Analysis after Longterm Followup [J].
Asano, Junpei ;
Watanabe, Takayuki ;
Oguchi, Takaya ;
Kanai, Keita ;
Maruyama, Masahiro ;
Ito, Tetsuya ;
Muraki, Takashi ;
Hamano, Hideaki ;
Arakura, Norikazu ;
Matsumoto, Akihiro ;
Kawa, Shigeyuki .
JOURNAL OF RHEUMATOLOGY, 2015, 42 (11) :2135-2142
[4]   Glutathione metabolism in cancer progression and treatment resistance [J].
Bansal, Ankita ;
Simon, M. Celeste .
JOURNAL OF CELL BIOLOGY, 2018, 217 (07) :2291-2298
[5]   The Role of IgG4 in the Fine Tuning of Tolerance in IgE-Mediated Allergy and Cancer [J].
Bianchini, Rodolfo ;
Karagiannis, Sophia N. ;
Jordakieva, Galateja ;
Jensen-Jarolim, Erika .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (14)
[6]   IgG4 drives M2a macrophages to a regulatory M2b-like phenotype: potential implication in immune tolerance [J].
Bianchini, Rodolfo ;
Roth-Walter, Franziska ;
Ohradanova-Repic, Anna ;
Flicker, Sabine ;
Hufnagl, Karin ;
Fischer, Michael Bernhard ;
Stockinger, Hannes ;
Jensen-Jarolim, Erika .
ALLERGY, 2019, 74 (03) :483-494
[7]   Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study [J].
Boyer, Michael ;
Sendur, Mehmet A. N. ;
Rodriguez-Abreu, Delvys ;
Park, Keunchil ;
Lee, Dae Ho ;
Cicin, Irfan ;
Yumuk, Perran Fulden ;
Orlandi, Francisco J. ;
Leal, Ticiana A. ;
Molinier, Olivier ;
Soparattanapaisarn, Nopadol ;
Langleben, Adrian ;
Califano, Raffaele ;
Medgyasszay, Balazs ;
Hsia, Te-Chun ;
Otterson, Gregory A. ;
Xu, Lu ;
Piperdi, Bilal ;
Samkari, Ayman ;
Reck, Martin .
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (21) :2327-+
[8]   Hyperprogressive disease: recognizing a novel pattern to improve patient management [J].
Champiat, Stephane ;
Ferrara, Roberto ;
Massard, Christophe ;
Besse, Benjamin ;
Marabelle, Aurelien ;
Soria, Jean-Charles ;
Ferte, Charles .
NATURE REVIEWS CLINICAL ONCOLOGY, 2018, 15 (12) :748-762
[9]   Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1 [J].
Champiat, Stephane ;
Dercle, Laurent ;
Ammari, Samy ;
Massard, Christophe ;
Hollebecque, Antoine ;
Postel-Vinay, Sophie ;
Chaput, Nathalie ;
Eggermont, Alexander ;
Marabelle, Aurelien ;
Soria, Jean-Charles ;
Ferte, Charles .
CLINICAL CANCER RESEARCH, 2017, 23 (08) :1920-1928
[10]   Lung cancer mutation profile of EGFR, ALK, and KRAS: Meta-analysis and comparison of never and ever smokers [J].
Chapman, Aaron M. ;
Sun, Kathie Y. ;
Ruestow, Peter ;
Cowan, Dallas M. ;
Madl, Amy K. .
LUNG CANCER, 2016, 102 :122-134